ArticleEClinicalMedicine2025

Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.

José Manuel Pérez-García et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.